Background The diagnostic challenges associated with the COVID‐19 pandemic resulted in
rapid development of diagnostic test methods for detecting SARS‐CoV‐2 infection. Serology …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread
worldwide as a severe pandemic. Although its seroprevalence is highly variable among …

Background While the leading symptoms during coronavirus disease 2019 (COVID-19) are
acute and the majority of patients fully recover, a significant fraction of patients now …

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is emerging as a global pandemic outbreak. To …

Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …

We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell
responses, soluble markers of inflammation, and antibody levels and neutralization capacity …

Interpretation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
serosurveillance studies is limited by poorly defined performance of antibody assays over …

Abstract Background Most SARS-CoV-2 infected patients develop IgG antibodies within 2–3
weeks after symptom onset. Antibody levels have been shown to gradually decrease in the …

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 is continuing to spread
globally. SARS-CoV-2 infections of feline and canine species have also been reported …

The clinical course of COVID-19 is very heterogeneous: most infected individuals can be
managed in an outpatient setting, but a substantial proportion of patients requires intensive …